

**From:** [Chasman, Daniel I., Ph.D.](#)  
**To:** [TOPMed ACC Publications](#); [Albert, Christine M.,M.D.,M.P.H.](#)  
**Cc:** [Sedlazeck, Fritz](#); [metcalf@bcm.edu](mailto:metcalf@bcm.edu)  
**Subject:** Re: TOPMed Manuscript Study-Specific Approval for WGHS  
**Date:** Friday, June 10, 2022 3:30:01 PM

---

**CAUTION: External Email \***

Confirmed. Fine with us!  
Thanks,  
Dan

---

**From:** TOPMed ACC Publications <topmed-pubs@westat.com>  
**Date:** Tuesday, June 7, 2022 at 4:52 PM  
**To:** "dchasman@research.bwh.harvard.edu" <DCHASMAN@research.bwh.harvard.edu>, "Albert, Christine M.,M.D.,M.P.H." <calbert@bwh.harvard.edu>  
**Cc:** TOPMed ACC Publications <topmed-pubs@westat.com>, "Sedlazeck, Fritz" <Fritz.Sedlazeck@bcm.edu>, "metcalf@bcm.edu" <metcalf@bcm.edu>  
**Subject:** TOPMed Manuscript Study-Specific Approval for WGHS

**External Email - Use Caution**

Good Afternoon, Drs. Albert and Chasman.

I am reaching out to you on behalf of the TOPMed ACC Publications Team to confirm [study-specific approval](#) for Dr. Fritz Sedlazeck's manuscript "[Structural variation across 138,134 samples in the TOPMed consortium](#)" using the WGHS data. This manuscript has TOPMed Structural Variation Working Group Approval (see attached) and formal approval to use WGHS data (proposal #[12856](#)).

I will attach this email to Dr. Sedlazeck's TOPMed manuscript submission. He is cc'd on this email should you have any follow-up questions.

Best,  
*Ashley Smith on behalf of the TOPMed ACC Publications Team*

**Ashley S. Smith, MPH, MLT(ASCP)**

WESTAT | Public Health & Epidemiology Practice

o: 240-314-2344

c: 678-596-6467

[AshleySmith@westat.com](mailto:AshleySmith@westat.com)

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Mass General Brigham Compliance HelpLine at <https://www.massgeneralbrigham.org/complianceline>.

Please note that this e-mail is not secure (encrypted). If you do not wish to continue communication over unencrypted e-mail, please notify the sender of this message immediately. Continuing to send or respond to e-mail after receiving this message means you understand and accept this risk and wish to continue to communicate over unencrypted e-mail.

\* Please use caution when responding and/or clicking on links as this email originated from outside of Westat.